Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection.
Chemotherapy
; 66(1-2): 24-32, 2021.
Article
in English
| MEDLINE | ID: covidwho-1147336
ABSTRACT
Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host's microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response ("gut-lung axis"). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Probiotics
/
Dysbiosis
/
Gastrointestinal Microbiome
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Traditional medicine
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Chemotherapy
Year:
2021
Document Type:
Article
Affiliation country:
000515344
Similar
MEDLINE
...
LILACS
LIS